GLP-1 Receptor Agonist: Health Care Savings or Healthcare Burden

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a topic of significant interest. Their potential benefits have sparked discussions among healthcare professionals and gained attention on social media. These agents represent a rare convergence of value and controversy in healthcare, with their significant advancements in treating type 2 diabetes mellitus (T2DM) and obesity. Beyond their clinical efficacy, GLP-1 RAs have substantial implications for healthcare economics, influencing both direct medical costs and broader economic outcomes. This article examines the financial impact of GLP-1 RAs, with a particular focus on their cost-effectiveness, healthcare expenditure, and policy considerations, to keep the audience informed and aware of the economic considerations in healthcare.